New vaccine aims to shield kids from hand, foot, and mouth disease
NCT ID NCT06754384
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested a new vaccine designed to protect against hand, foot, and mouth disease and herpangina, which are common viral infections in children. The trial involved 552 healthy adults and children aged 6 months to 12 years. Participants received either a low, medium, or high dose of the experimental vaccine or a control vaccine, and researchers monitored safety and immune responses.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- tetravalent inactivated enterovirus vaccine (Vero cell)
- What this could lead to
- If successful, this vaccine could help prevent hand, foot, and mouth disease and herpangina caused by multiple enterovirus types.
- What could go wrong
- This is an early-phase trial (Phase I/II) focused on safety and immune response, not yet proven to prevent disease. Results may not confirm effectiveness in real-world settings.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HAND, FOOT, AND MOUTH DISEASE(HFMD) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Zhejiang Provincial Center for Disease Control and Prevention
Hangzhou, Hangzhou, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.